1700001E04Rik Activators
1700001E04Rik Activators are a diverse array of chemical compounds that indirectly promote the functional activity of 1700001E04Rik through their influence on specific signaling pathways. Compounds such as Forskolin and IBMX operate by increasing intracellular cAMP levels, thus activating protein kinase A (PKA), a kinase known to phosphorylate various substrates that may interact with pathways that involve 1700001E04Rik, leading to its functional enhancement. Similarly, PMA, through activation of protein kinase C (PKC), and epigallocatechin gallate, a broad-spectrum kinase inhibitor, contribute to the indirect activation of 1700001E04Rik by modulating phosphorylation events within the cell.
1700001E04Rik activators encompass a range of chemical compounds that indirectly facilitate the enhancement of 1700001E04Rik function by manipulating distinct cellular signaling mechanisms. Forskolin and IBMX elevate intracellular cAMP, subsequently activating PKA, which can phosphorylate proteins within the signaling pathways that 1700001E04Rik operates in, thereby indirectly enhancing its activity. Similarly, PMA, as a PKC activator, and epigallocatechin gallate, by inhibiting various kinases, may relieve negative regulatory influences on the pathways relevant to 1700001E04Rik, resulting in an upsurge in its functional activity. LY294002 and Wortmannin, both PI3K inhibitors, could dismantle inhibitory feedback loops within cellular signaling networks, thereby indirectly augmenting the activity of 1700001E04Rik. The lipid signaling modulator sphingosine-1-phosphate and the calcium ionophore A23187 also contribute to the amplification of 1700001E04Rik activity by influencing lipid and calcium-dependent pathways, respectively, which are expected to intersect with 1700001E04Rik's signaling cascade.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX works to increase cAMP by inhibiting phosphodiesterases, which degrade cAMP. Elevated cAMP levels indirectly activate pathways that 1700001E04Rik is involved in, thus enhancing its functional activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which is known to phosphorylate a wide variety of protein targets that could include substrates involved in the functional pathways of 1700001E04Rik, indirectly enhancing its activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate inhibits various kinases, which may remove competitive inhibition on signaling cascades relevant to 1700001E04Rik, thereby enhancing its activity indirectly through these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which may alleviate inhibitory control over cellular pathways that involve 1700001E04Rik, indirectly upregulating its activity by altering the downstream signaling environment. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, another PI3K inhibitor, similarly to LY294002, could lift inhibitory signals that suppress pathways involving 1700001E04Rik, allowing for an increase in its functional activity through indirect means. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate enhances 1700001E04Rik activity by modulating lipid signaling pathways that intersect with signaling cascades involving 1700001E04Rik, thereby providing an indirect activation mechanism. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as an ionophore for calcium, increasing intracellular calcium levels which can activate calcium-dependent signaling pathways that are likely to intersect with 1700001E04Rik's signaling pathways, enhancing its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAPK, which may shift signaling dynamics to favor the activation of pathways that 1700001E04Rik is involved in, thereby indirectly enhancing its activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin increases intracellular calcium by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), which likely affects calcium signaling pathways involving 1700001E04Rik, enhancing its activity indirectly. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, may enhance the activity of 1700001E04Rik by reducing competition in tyrosine kinase signaling, which could indirectly activate signaling pathways involving 1700001E04Rik. | ||||||